Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers and Extracellular Vesicles Europe 2024

Raymond Schiffelers's Biography



Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht

Raymond Schiffelers studied Bio-Pharmaceutical Sciences at Leiden University (1990-1995). After an industrial traineeship at SmithKline Beecham Pharmaceuticals (UK) he did his PhD in medical microbiology at Erasmus University Rotterdam on liposomal targeting of antimicrobial agents (1996-2001). Subsequently he became post-doc at Utrecht University working on liposomes targeting tumor vasculature. In 2002-2003, at Intradigm Co (USA) he expanded his tumor vasculature-targeting work with polymers for delivery of siRNA. After his return to Utrecht University he became assistant and then associate professor. He received an ERC Consolidator Grant in 2010 to investigate extracellular vesicles as biological drug delivery systems. After he moved to University Medical Center Utrecht in 2011 he became professor of nanomedicine working on bio-inspired and synthetic drug delivery systems. He coordinates two H2020 projects on this topic, B-SMART and EXPERT, is editor for the International Journal of Pharmaceutics, Journal of Controlled Release and Journal of Extracellular Vesicles, and is founder of EXCYTEX-an extracellular vesicle-based company. Since 2021 he also works part-time for Nanocell Therapeutics as VP Preclinical R&D and is president of the ETPN.

Raymond Schiffelers Image

Nanospresso: Microfluidic Mixing of Nucleic Acids and Excipients to Make Nanomedicines

Monday, 24 June 2024 at 14:00

Add to Calendar ▼2024-06-24 14:00:002024-06-24 15:00:00Europe/LondonNanospresso: Microfluidic Mixing of Nucleic Acids and Excipients to Make NanomedicinesCirculating Biomarkers and Extracellular Vesicles Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Lipid nanoparticles are the frontrunner nanomedicines for the delivery of nucleic acid therapeutics. The COVID-19 mRNA vaccines were built on this technology. These lipid nanoparticles self-assemble around the mRNA through electrostatic and hydrophobic interactions. For mass production of lipid nanoparticles (like vaccines during a pandemic) impingement jet technology provides high throughput. For smaller batches, microfluidic mixing can provide an excellent platform for making high quality lipid nanoparticles. In the project NANOSPRESSO, we take this concept one step further to explore microfluidic mixing of personalized lipid nanoparticles in a cartridge for a single dose for a single patient produced in the hospital pharmacy. This concept offers attractive properties for the democratization of personalized healthcare.


Add to Calendar ▼2024-06-24 00:00:002024-06-25 00:00:00Europe/LondonCirculating Biomarkers and Extracellular Vesicles Europe 2024Circulating Biomarkers and Extracellular Vesicles Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com